CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Intra-articular Stromal Vascular Fraction Injectionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06562101
NCT06562101N/ACompleted

Effects of Intra-articular Stromal Vascular Fraction Injection on Clinical Symptoms and Cartilage Health in Osteoarthritic Knees: A Single-Center Pilot Study

Shu-Hao Chang, MD·interventional·Posted Aug 20, 2024·Updated Aug 20, 2024

In Brief

A clinical study evaluating Intra-articular Stromal Vascular Fraction Injection for Osteoarthritis, Knee. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Background: Osteoarthritis (OA) is a prevalent form of arthritis worldwide. Intra-articular stromal vascular fraction (SVF) injections are a potential therapeutic option for patients with OA. This study aims to assess the effects of intra-articular SVF injections on knee OA. Methods: Ten patients with knee OA participated in this study. After being administered intra-articular SVF injections, their outcomes were evaluated using various questionnaires. MRI T2 mapping was conducted and compared before the intervention and 6 months after. All data underwent analysis using various tests.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 20, 2024
Enrollment StartDec 4, 2020
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 1.9 years ago

Interventions

Intra-articular Stromal Vascular Fraction Injectionprocedure

Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.